Ion Beam (IBAB) | Stock Overview & Key Data
Ion Beam Applications S.A. | Mid-cap | Healthcare
Ion Beam Applications S.A. | Mid-cap | Healthcare
Ion Beam Performance Comparison
Stock Range
Today's Range
Low: €10.82
High: €11.10
on September 23, 2025
52 Week Range
Low: €9.40
High: €15.14
on April 7, 2025
on October 11, 2024
All-Time High: €56.94 on May 8, 2017
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€323.7M
EPS
0.58
P/E Ratio (TTM)
18.76
Forward P/E
10.88
P/B Ratio
2.88
PEG Ratio
10.88
Div. Yield
3.51%
ROE
16.20%
Beta
0.915
Debt to Equity
56.98
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
2.30%
Profit Margin
2.89%
Returns and Earnings
Return on Assets (TTM)
3.89%
Return on Equity (TTM)
16.20%
EBITDA
€24.2M
Net Income (TTM)
€17.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€19.96
Quarterly Revenue Growth (YoY)
47.70%
Quarterly Earnings Growth (YoY)
N/A
Dividend Information
Last 12-Month Dividend
€0.41
Current Dividend Yield
3.51%
3-Year Average Dividend Yield
1.46%
3-Year Average Annual Dividend
€0.27
3-Year Total Dividends
€0.81
Ex-Dividend Date
June 18, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ion Beam IBAB | 323.69M Mid-cap | -2.48% | -8.77% | -6.61% | -0.18% | -19.21% | -17.39% | -8.17% | 2.80% |
| Sequana Medical NV SEQUA | 60.97M Small-cap | -6.00% | -8.74% | -27.69% | -10.48% | -61.63% | -1.05% | -85.27% | -84.59% |
| Argenx SE ARGX | 38.42B Large-cap | -0.57% | 6.27% | 34.55% | 10.97% | 2.65% | 30.98% | 70.15% | 175.48% |
| UCB S.A UCB | 39.10B Large-cap | 0.25% | 1.69% | 24.33% | 13.90% | 6.82% | 26.68% | 187.40% | 109.34% |
| Fagron NV FAGR | 1.43B Large-cap | -1.21% | -5.08% | -12.69% | 2.40% | 16.95% | 5.72% | 55.68% | -9.93% |
| Onward Medical N.V ONWD | 238.02M Mid-cap | 2.90% | 4.10% | 21.69% | 11.97% | -0.19% | 4.10% | 0.57% | -58.16% |
Ownership & Short Interest
Insider Ownership
34.63%
Institutional Ownership
26.17%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
23K
Average 90-Day Volume
18K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is IBAB's 52-week high and low?
- In the last 52 weeks, Ion Beam reached a high of €15.14 (on October 11, 2024) and a low of €9.40 (on April 7, 2025).
- What is the market cap and P/E ratio for IBAB?
- Curious about Ion Beam's size and valuation? Its market capitalization stands at 323.69M. When it comes to valuation, the P/E ratio (trailing twelve months) is 18.76, and the forward P/E (looking ahead) is 10.88.
- Does IBAB pay dividends? If so, what's the yield?
- Yes, Ion Beam is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.51%, and the company has paid an average of €0.27 per share annually over the past 3 years.
- Who are Ion Beam's main competitors or similar companies to consider before investing?
When looking at Ion Beam, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sequana Medical NV
SEQUA60.97M Healthcare Medical Devices -1.05% -85.27% Argenx SE
ARGX38.42B Healthcare Biotechnology 30.98% 70.15% UCB S.A
UCB39.10B Healthcare Biotechnology 26.68% 187.40% Fagron NV
FAGR1.43B Healthcare Drug Manufacturers - Specialty & Generic 5.72% 55.68% Onward Medical N.V
ONWD238.02M Healthcare Biotechnology 4.10% 0.57% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Ion Beam Applications S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Ion Beam's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 16.20%, the Debt to Equity ratio from the most recent quarter is 56.98, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for IBAB?
- Looking at Ion Beam's growth, its revenue over the trailing twelve months (TTM) was €586M. Compared to the same quarter last year (YoY), quarterly revenue grew by 47.70%, and quarterly earnings saw a YoY growth of N/A.
- How much of IBAB stock is held by insiders and institutions?
- Wondering who owns Ion Beam stock? Company insiders (like executives and directors) hold about 34.63% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 26.17%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.